



Date: November 09, 2023

To,  
The Manager,  
Listing Department,  
National Stock Exchange of India Ltd.,  
Exchange Plaza,  
Plot No. C-1, Block G,  
Bandra Kurla Complex,  
Bandra (E)  
Mumbai – 400051.

**Symbol: UNIHEALTH**

Dear Sir/ Madam,

**Sub: Press Release - UniHealth Reports PAT of ₹ 430 Lakhs in H1 FY24**

In terms of Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, enclosed herewith is a copy of the Press Release made by the Company.

A copy of the press release is also being uploaded on the Company's website: [www.unihealthonline.com](http://www.unihealthonline.com).

You are requested to take the same on record.

Thanking you,

Yours faithfully,

For Unihealth Consultancy Limited  
(Formerly Unihealth Consultancy Private Limited)

**PRAJAKTA** Digitally signed  
by PRAJAKTA  
**SURESH** SURESH BHOR  
**BHOR** Date: 2023.11.09  
12:03:21 +05'30'



Prajakta Bhore  
Company Secretary/ Compliance Officer

**UniHealth Consultancy Limited**

Registered Office : H-13/14, Everest, 156, Tardeo Road, Mumbai - 400 034, Maharashtra, India.

+91 22 2354 4625 / 27 info@unihealthonline.com www.unihealthonline.com | www.umchospitals.com

CIN No.: U85100MH2010PLC200491



## UniHealth Reports PAT of ₹ 430 Lakhs In H1 FY24.

**Mumbai, November 8, 2023: UniHealth Consultancy Limited. (NSE – UNIHEALTH)**, a global healthcare service provider, announced its unaudited Financial Results for H1 FY24.

### H1 FY24 Key Financials at a Glance:

Particulars (₹ Lakhs)	H1 FY24	
	Consolidated	Standalone
Total Income	2,285.29	187.83
EBITDA	784.46	64.39
EBITDA Margin (%)	34.33	34.28
Profit After Tax	429.76	49.61
Profit After Tax Margin (%)	18.81	26.41
EPS (₹)	3.15	0.43

**Commenting on the performance, Dr. Akshay Parmar, Founder & Managing Director of UniHealth Consultancy said,** “We are delighted to announce significant developments in our growth journey. We’re expanding our team and acquiring new office space to support our multi-vertical expansion. In Tanzania, we’re exploring the management or acquisition of a dialysis center and polyclinic in Dar-es-Salaam. This move will substantially boost our presence in the region.

We’re in discussions with Air Tanzania and Myanmar Airways International to launch unique Medical Travel Programs, enhancing our market share. Our Board's approval to extend debt to UniHealth Pharmaceuticals Private Limited will facilitate product distribution in Uganda and Nigeria.

With successful IPO funding and positive industry trends, we’re proactively expanding in key geographies, broadening our service portfolio, and nurturing future leaders within our organization to support growth across all business verticals.”

### About UniHealth Consultancy Limited:

**UniHealth Consultancy Limited (NSE – UNIHEALTH)**, established in 2010 in Mumbai, is a prominent global healthcare service provider with a strong presence in Africa. The company operates in various healthcare sectors, encompassing medical centers, hospitals, consultancy services, pharmaceutical distribution, and medical travel.

Through its subsidiary, UniHealth Pharmaceuticals, it specializes in procuring and exporting pharmaceutical products, serving hospitals in Uganda, Nigeria, and Tanzania. Under the 'UMC Hospitals' brand, UniHealth manages two multi-speciality facilities with a combined 200-bed capacity in Uganda and Nigeria, along with a dialysis center in Tanzania. Additionally, UniHealth is actively involved in healthcare consultancy projects in Kenya and Angola and serves as a reliable distributor for Indian pharmaceutical companies across various African nations.

The Company was successfully listed on the NSE Emerge in September 2023.

In FY23, the company reported Revenue of ₹ 4,603.01 Lakhs, EBITDA of ₹ 1,691.53 Lakhs and PAT of ₹ 765.67 Lakhs.

**Disclaimer:**

Certain statements in this document that are not historical facts are forward looking statements. Such forward-looking statements are subject to certain risks and uncertainties like government actions, local, political or economic developments, technological risks, and many other factors that could cause actual results to differ materially from those contemplated by the relevant forward-looking statements. The Company will not be in any way responsible for any action taken based on such statements and undertakes no obligation to publicly update these forward-looking statements to reflect subsequent events or circumstances.

**For further information please contact:**



Sunil Mudgal  
Kirin Advisors Private Limited  
[sunil@kirinadvisors.com](mailto:sunil@kirinadvisors.com)  
M - 9869275849